CARDIOVASCULAR MEDICINE

Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population

M Nakamura, H Endo, M Nasu, N Arakawa, T Segawa, K Hiramori

Second Department of Medicine, Iwate Medical University, Morioka, Japan

Correspondence to:
Correspondence to:
Dr M Nakamura, Second Department of Internal Medicine, Iwate Medical University, 19–1 Uchimaru, Morioka, Iwate 020–8505, Japan;
nkmrmoto{at}iwate-med.ac.jp

Background: Conflict exists regarding the usefulness of measuring plasma B type natriuretic peptide (BNP) concentrations for identifying impaired left ventricular (LV) systolic function during mass screening. Various cardiac abnormalities, regardless of degree of LV dysfunction, are prone to carry a high risk of cardiovascular events.

Objective: To examine the validity of plasma BNP measurement for detection of various cardiac abnormalities in a population with a low prevalence of coronary heart disease and LV systolic dysfunction.

Design and setting: Participants in this cross sectional study attended a health screening programme in Iwate, northern Japan. Plasma BNP concentrations were determined in 1098 consecutive subjects (mean age 56 years) by direct radioimmunoassay. All subjects underwent multiphasic health checkups including physical examination, ECG, chest radiography, and transthoracic echocardiography.

Results: Conventional diagnostic methods showed 39 subjects to have a wide range of cardiac abnormalities: lone atrial fibrillation or flutter in 11; previous myocardial infarction in seven; valvar heart disease in seven; hypertensive heart disease in six; cardiomyopathy in six; atrial septal defect in one; and cor pulmonale in one. No subjects had a low LV ejection fraction (< 40%). To assess the utility of plasma BNP measurement for identification of such patients, receiver operating characteristic analysis was performed. The optimal threshold for identification was a BNP concentration of 50 pg/ml with sensitivity of 89.7% and specificity of 95.7%. The area under the receiver operating characteristic curve was 0.970. The positive and negative predictive values at the cutoff level were 44.3% and 99.6%, respectively.

Conclusion: Measurement of plasma BNP concentration is a very efficient and cost effective mass screening technique for identifying patients with various cardiac abnormalities regardless of aetiology and degree of LV systolic dysfunction that can potentially develop into obvious heart failure and carry a high risk of a cardiovascular event.

Keywords: B type natriuretic peptide; left ventricular function; screening

Abbreviations: BNP, B type natriuretic peptide; CI, confidence interval; LV, left ventricular; MONICA, monitoring trends and determinants in cardiovascular disease

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Watanabe, H., Hirayama, M., Noda, A., Ito, M., Atsuta, N., Senda, J., Kaga, T., Yamada, A., Katsuno, M., Niwa, T., Tanaka, F., Sobue, G. (2009). B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist. Neurology 72: 621-626 [Abstract] [Full Text]  
• Huelsmann, M., Neuhold, S., Strunk, G., Moertl, D., Berger, R., Prager, R., Abrahamian, H., Riedl, M., Pacher, R., Luger, A., Clodi, M. (2008). NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 29: 2259-2264 [Abstract] [Full Text]  
• Maisel, A., Mueller, C., Adams, K. Jr., Anker, S. D., Aspromonte, N., Cleland, J. G.F., Cohen-Solal, A., Dahlstrom, U., DeMaria, A., Di Somma, S., Filippatos, G. S., Fonarow, G. C., Jourdain, P., Komajda, M., Liu, P. P., McDonagh, T., McDonald, K., Mebazaa, A., Nieminen, M. S., Peacock, W. F., Tubaro, M., Valle, R., Vanderhyden, M., Yancy, C. W., Zannad, F., Braunwald, E. (2008). State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10: 824-839 [Abstract] [Full Text]  
• Parthenakis, F. I., Patrianakos, A. P., Haritakis, C. N., Zacharis, E. A., Nyktari, E. G., Vardas, P. E. (2008). NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy. Eur J Heart Fail 10: 475-481 [Abstract] [Full Text]  
• Daniels, L. B., Maisel, A. S. (2007). Natriuretic Peptides. J Am Coll Cardiol 50: 2357-2368 [Abstract] [Full Text]  
• Cortes, R., Rivera, M., Salvador, A., Bertomeu, V., de Burgos, F. G., Rosello-Lleti, E., Portoles, M., Paya, R., Martinez-Dolz, L., Climent, V. (2007). Variability of NT-proBNP plasma and urine levels in patients with stable heart failure: a 2-year follow-up study. Heart 93: 957-962 [Abstract] [Full Text]  
• Choi, S., Park, D., Lee, S., Hong, Y., Kim, S., Lee, J. (2007). Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean patients visiting emergency departments. Emerg. Med. J. 24: 343-347 [Abstract] [Full Text]  
• Date, T, Yamane, T, Inada, K, Matsuo, S, Miyanaga, S, Sugimoto, K, Shibayama, K, Taniguchi, I, Mochizuki, S (2006). Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation. Heart 92: 1623-1627 [Abstract] [Full Text]  
• McKie, P. M., Rodeheffer, R. J., Cataliotti, A., Martin, F. L., Urban, L. H., Mahoney, D. W., Jacobsen, S. J., Redfield, M. M., Burnett, J. C. Jr (2006). Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure. Hypertension 47: 874-880 [Abstract] [Full Text]  
• Clerico, A., Recchia, F. A., Passino, C., Emdin, M. (2006). Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290: H17-H29 [Abstract] [Full Text]  
• McKie, P. M., Burnett, J. C. Jr (2005). B-Type Natriuretic Peptide as a Biomarker Beyond Heart Failure: Speculations and Opportunities. Mayo Clin Proc. 80: 1029-1036 [Abstract]  
• Valle, R., Aspromonte, N., Barro, S., Canali, C., Carbonieri, E., Ceci, V., Chinellato, M., Gallo, G., Giovinazzo, P., Ricci, R., Milani, L. (2005). The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail 7: 542-551 [Abstract] [Full Text]  
• Rodeheffer, R. J. (2004). Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?. J Am Coll Cardiol 44: 740-749 [Abstract] [Full Text]  
• Pfister, R., Scholz, M., Wielckens, K., Erdmann, E., Schneider, C.A. (2004). Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6: 289-293 [Abstract] [Full Text]  
• Schinkel, A F L, Vourvouri, E C, Bax, J J, Boomsma, F, Bountioukos, M, Rizzello, V, Biagini, E, Agricola, E, Elhendy, A, Roelandt, J R T C, Poldermans, D (2004). Relation between left ventricular contractile reserve during low dose dobutamine echocardiography and plasma concentrations of natriuretic peptides. Heart 90: 293-296 [Abstract] [Full Text]  
• de Denus, S., Pharand, C., Williamson, D. R. (2004). Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone. Chest 125: 652-668 [Abstract] [Full Text]  
• Nielsen, L. S., Svanegaard, J., Klitgaard, N. A., Egeblad, H. (2004). N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6: 63-70 [Abstract] [Full Text]  
• Clerico, A., Emdin, M. (2004). Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clin. Chem. 50: 33-50 [Abstract] [Full Text]  
• Vourvouri, E. C., Schinkel, A. F.L., Roelandt, J. R.T.C., Boomsma, F., Sianos, G., Bountioukos, M., Sozzi, F. B., Rizzello, V., Bax, J. J., Karvounis, H. I., Poldermans, D. (2003). Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Fail 5: 767-774 [Abstract] [Full Text]  
• D'Souza, S P, Baxter, G F (2003). B Type natriuretic peptide: a good omen in myocardial ischaemia?. Heart 89: 707-709 [Full Text]  
• Struthers, A D (2002). Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 87: 97-98 [Full Text]